BioPharma Drug Approval

Japan Accelerates Approval Process for Groundbreaking Urothelial Cancer Treatment by Astellas

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas")  announced that Japan's Ministry of Health, Labour a...

 February 19, 2024 | News

AffaMed's NDA for DEXTENZA Accepted by Singapore HSA for Post-Surgery Ocular Treatment

AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products&...

 February 19, 2024 | News

Synbio Tech's Probiotic TWK10 Earns Taiwan FDA Approval for Anti-fatigue Health Claim

Synbio Tech is thrilled to announce that its groundbreaking probiotic strain, Lactiplantibacillus plantarum TWK10, has been awarded a prestigious...

 February 19, 2024 | News

Jacobio Gains China CDE Approval for Phase III SHP2 and KRAS G12C Inhibitor Trial

This approved study in China is a randomized active controlled phase III trial design to evaluate the efficacy and safety of JAB-3312 in combinat...

 February 19, 2024 | News

Japan Becomes First in the World to Approve Dupixent® for Chronic Spontaneous Urticaria (CSU)

  Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth appr...

 February 17, 2024 | News

AstraZeneca's TAGRISSO® (osimertinib) with Chemotherapy Approved in the US for EGFR-Mutated Advanced Lung Cancer

AstraZeneca’s TAGRISSO® (osimertinib) with the addition of chemotherapy has been approved in the US for the treatment of adult patients with...

 February 17, 2024 | News

FDA Prioritizes Review of Bristol Myers Squibb's Augtyro™ for NTRK-Positive Solid Tumors

Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for A...

 February 15, 2024 | News

Innovent Biologics Advances Novel Weight Management Drug Mazdutide with NDA Acceptance in China

  This groundbreaking achievement marks mazdutide as the first GLP-1R/GCGR dual agonist to successfully complete Phase 3 trials in support of an NDA ...

 February 08, 2024 | Regulatory

Luye Pharma Licenses Rivastigmine Patch to Myung In Pharm for South Korea Commercialization

The agreement for the collaboration was signed at a ceremony attended by executives from both sides. Dianbo Liu, Chairman of the Board of Directors of Luye...

 February 06, 2024 | News

Acepodia Gains FDA Clearance for ACE2016, Initiates Phase 1 Study on Solid Tumor Treatment

This clearance marks a significant milestone for Acepodia, allowing the initiation of a Phase 1, first-in-human clinical trial to assess th...

 February 05, 2024 | News

Biosyngen's BST02 Granted FDA Fast Track for Liver Cancer Treatment

Fast track is a process designed to facilitate development, and accelerate the review of drugs to treat serious or life-threatening conditions and fill an ...

 February 02, 2024 | News

Vertex's Breakthrough VX-548: Transforming Pain Management with Rapid Relief and Safety, A New Era in Acute Pain Solutions

Treatment with VX-548 led to statistically significant improvement in pain compared to placebo as well as a clinically meaningful reduction in pain from ...

 January 31, 2024 | News

CellVax Therapeutics Receives FDA Clearance for FK-PC101 Cancer Immunotherapy IND

FK-PC101 is CellVax's novel personalized cancer immunotherapy intended to treat prostate cancer patients who have a high risk of recurrence after prostatec...

 January 30, 2024 | News

Oricell's OriCAR-017 CAR-T Therapy IND Cleared by FDA for Relapsed/Refractory Multiple Myeloma

OriCAR-017 is a chimeric antigen receptor (CAR) T cell therapy targeting GPRC5D. The therapy leverages Oricell's proprietary platforms including Ori®Ab...

 January 30, 2024 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close